ArticleBMC cancer2025
Pharmacological targeting and characterization of Voltage-Gated Sodium Channels (VGSCs) expressed in the high-grade glioma microenvironment.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ion Channel-Targeting Modulators in Glioma: Pharmacological Advances and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundHigh-grade glioma (HGG) cells reactivate neurodevelopmental programs regulated by ion channels to drive tumor progression. The activity of voltage-gated sodium channels (VGSCs) is fundamental to development, a target of blood-brain barrier (BBB)-permeable FDA-approved drugs, and aids tumor advancement in several cancers. However, the contribution of VGSC activity to HGG pathology remains unknown.
methodsUsing single-cell and spatial transcriptomics, proteomics, and immunohistochemistry, we profiled the expression landscape of the VGSC family in patient tumors from two HGGs: adult glioblastoma and pediatric diffuse midline glioma (DMG). We further validated VGSC expression and function in HGG patient-derived cell lines using RNA, protein, and electrophysiological analyses, and assessed the anticancer efficacy of VGSC-modulating drugs in vitro through cell viability and invasion assays.
resultsVGSCs α subunits targeted by different classes of VGSC-drugs are differentially expressed within DMG and glioblastoma. Overall, VGSCs that are sensitive to the neurotoxin, tetrodotoxin (TTX), and in normal physiology are expressed in the nervous system were upregulated by invasive HGG cells at the leading edge of DMG and glioblastoma tumors. Whereas the TTX-insensitive cardiac VGSC NaV1.5 was distinctly more abundant within the cellular tumor of the DMG microenvironment. VGSC-expressing HGG cells within both microenvironments receive oncogenic glutamatergic inputs from surrounding neurons. RNA, protein and electrophysiological analysis of patient-derived HGG cells supported our in vivo findings, where NaV1.5 plays a significant role in DMG cell lines, conducting TTX-insensitive transient and persistent sodium currents. Overall, VGSC-targeting drugs had limited anticancer efficacy; however, GS967 a persistent current blocker, significantly inhibited the invasiveness of a DMG cell line by ~ 33%.
conclusionInhibiting intrinsic VGSC persistent currents suppresses invasiveness in DMG subpopulations and may further hinder HGG progression by buffering oncogenic depolarizations from neuron-glioma synaptic activity. Therefore, VGSC-drugs targeting persistent sodium currents offer untapped therapeutic options for treating HGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.